21–24 Here we used novel computer-assisted analysis techniques to non-invasively assess FAZ diameter and the architecture of the fovea in preterm children, and examined whether foveal vascular ...

The new PDUFA target date is March 18, 2025. The Food and Drug Administration (FDA) has extended the review period for the Biologics License Application (BLA) for NT-501 (revakinagene taroretcel) in ...

Baseline AL (B = 0.561, OR = 1.752, P = 0.033), parafoveal choroidal thickness changes per year (B = - 0.094, OR = 0.910, P = 0.032), foveal retinal vascular density changes per year (B = 0.104, OR = ...

When a club "non-tenders" a player, it declines to give that player a contract for the upcoming season, thereby immediately making him a free agent. Players on the 40-man roster with fewer than six ...

Use of immunomodulatory treatment for non-infectious uveitis: an International Ocular Inflammation Society report of real-world practice ...

Developments in non-invasive retinal imaging technologies, including optical coherence tomography (OCT), OCT angiography and digital retinal photography, have provided a means to study neuronal and ...

Angela Merkel’s memoir Freedom offers an unprecedented look into the life and mind of one of the world’s most influential leaders. Spanning her childhood in East Germany, the seismic events of 1989, ...

A delay in the FDA decision for NT-501 could leave those with macular telangiectasia (MacTel) without any form of treatment for longer than anticipated. Macular telangiectasia (MacTel) type 2 ...

DNA damage is key factor in age-related macular degeneration Targeting specific retinal cell types could lead to treatments that slow or stop progression Date: December 3, 2024 Source: University ...